Z Trim Holdings Sales Growth Continues in July 2012

MUNDELEIN, Ill., Aug. 20, 2012 /PRNewswire/ -- Z Trim Holdings, Inc. (OTC Markets: ZTHO), a bio- technology company providing value-added ingredients to a variety of industries, today announced that it recorded, in July 2012, over 4 times the sales revenues that it recorded in July 2011.  "We believe we have moved past seasonality issues with respect to our sales cycle, and expect to have steady sales, month-to-month and season-to-season," said Steve Cohen, Z Trim CEO.  "Our continued sales growth is indicative of how well our food ingredients can assist food manufacturers to both lower costs and provide better, healthier products to consumers.   As we continue to get the word out about our industrial products, we hope to see similar results in our industrial ingredients division."

ABOUT Z TRIM®

Z Trim Holdings, Inc. (www.ztrim.com) is a bio-technology company that owns existing, and has developed new, products and processes to make use of biomass for uses in the food and industrial markets.   The Company's food division currently sells a line of products to the food industry that can help food manufacturers reduce their costs and help them solve many production problems.  The Company's revolutionary technology provides value-added ingredients across virtually all food industry categories.  The Company's all-natural products, among other things, help to reduce fat and calories, add fiber, provide shelf-stability, prevent oil migration, and add binding capacity – all without degrading the taste and texture of the final food products.  Perhaps most significantly, Z Trim's products can help extend finished products, and thereby increase its customers' gross margins.  The Company's industrial division, opened in 2012, plans to sell eco-friendly ingredients to oil drilling, hydraulic fracturing, petroleum coke, steel/aluminum, paper and other industries.  The Company's industrial ingredients are highly functional in applications for adhesives, binders, viscofiers and emulsifiers.

Forward-Looking Statements and Risk Factors

Certain statements in this press release are "forward−looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of Z Trim Holdings to be materially different from any future results, performance or achievements expressed or implied by these forward−looking statements. Other factors, which could materially affect such forward−looking statements, can be found in our filings with the Securities and Exchange Commission at www.sec.gov, including risk factors relating to our history of operating losses, that our auditors have expressed substantial doubt regarding our ability to continue as a going concern, the fact that we may dilute existing shareholders through additional stock issuances, and our reliance on our intellectual property. Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward−looking statements and are cautioned not to place undue reliance on such forward−looking statements. The forward−looking statements made herein are only made as of the date of this press release and we undertake no obligation to publicly update such forward−looking statements to reflect subsequent events or circumstances.

Contacts:

Media:

Investors:



Angela Strickland

Thomas Wagner

(847) 549-6002

Legend Securities, Inc.

[email protected]

718-233-2627




John Columbia


Legend Securities, Inc.


718-233-2677



SOURCE Z Trim Holdings, Inc.

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.